PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

JUN 1 0 2015 (he Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Whatitute of Torm1449A-PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/086,072
Filing Date	February 27, 2002
First Named Inventor	Laurie DELEVE
Art Unit	1617
Examiner Name	Sharareh, Shahnam J.
Attorney Docket Number	13761-7065; US7000692001

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No. <sup>1</sup>	Number – Kind Code <sup>2</sup> (if known)	MM-DD-YY	Application of Cited Document	Where Relevant Passages or Relevant Figures Appear
7	1	US-6,274,136 B1	08/14/01	Weiner et al.	
		US-			
,		US-			
		US-			
•		US-			
		US-			
		US-		·	

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials* No.1	Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)	MM-DD-YY	Application of Cited	Where Relevant Passages		
· · · · · · · · · · · · · · · · · · ·				Document	or Relevant Figures Appear	T⁰
<del></del>						-
					<del> </del>	╀
	<del> </del>					├
					<del> </del>	$\vdash$
						╁┈
				·		┢
		·				

Examiner's Signature	Glat	Date Considered	8/18/05
			, , , , , , , , , , , , , , , , , , , ,

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

form 1449B-PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known	
Application Number	10/086,072
Filing Date	February 27, 2002
First Named Inventor	Laurie DELEVE
Art Unit	1617
Examiner Name	Sharareh, Shahnam J.
Attorney Docket Number	13761-7065; US7000692001

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal		
7	1	BARNETT, L. et al. "Virus Encoding an Encephalitogenic Peptide Protects Mice from Experimental Allergic Encephalomyelitis" Journal of Neuroimmunology (1996) 64:163-173.		
	2	CRYSTAL R. G. "Transfer of Genes to Humans: Early Lessons and Obstacles to Success" Science (1995) 270:404-410.		
	3	DeLEVE, L. D. et al. "Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) in the Rat is Prevented by Matrix Metalloproteinase Inhibition" <i>Gastroenterology</i> (2003) 125:882-890.		
	4	KALDEN, J. R. et al. "Immunological Treatment of Autoimmune Diseases" Advances in Immunology (1998) 68:333 -418.		
	5	MILLER, S. D. and W. J. KARPYS "The Immunopathogenesis and Regulation of T-Cell-Mediated Demyelinating Diseases" <i>Immunology Today</i> (1994) <b>15</b> (8):356-361.		
	6	TAMURA, Y. et al. "Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives" J. Med. Chem. (1998) 41(4):640-649.		
	7.	WADA, C. K. et al. "Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors" J. Med. Chem. (2002) 45:219-232.		
	8	WHITTAKER, M. et al. "Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors" Chem Rev. (1999) 99:2735-2776.	-	
	9	WILLENBORG, D. and M. A. STAYKOVA "Approaches to the Treatment of Central Nervous System Autoimmune Disease Using Specific Neuroantigen" <i>Immunology and Cell Biology</i> (1998) <b>76</b> :91-103.		
8	10	YU, M. et al. "A Predictable Sequential Determinant Spreading Cascade Invariably Accompanies Progression of Experimental Autoimmune Encephalomyelitis: A Basis for Peptide-Specific Therapy After Onset of Clinical Disease"  J. Exp. Med. (April 1996) 183:1777-1788		
Examiner's Signature		Date		

<sup>\*</sup> EXAMINER: Initial if reference considered. whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered,

Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.